StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.25 | $1.17 | -6.40% | 0.1M |
| 05-12 | $1.18 | $1.25 | +5.93% | 0.1M |
| 05-13 | $1.28 | $1.29 | +0.78% | 0.1M |
| 05-14 | $1.28 | $1.32 | +3.13% | 0.1M |
| 05-15 | $1.30 | $1.26 | -3.08% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Each factor shows ENTX's percentile within the scored universe — observational ranking, not a recommendation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
| Metric | Q3 2026 (Est.) Expected 2026-08-06 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $42.00K | $42.00K | $42.00K |
Operating Income | Not available | $-3.54M | $-11.53M | $-8.49M | $-5.23M |
Net Income | Not available | $-3.50M | $-11.44M | $-8.42M | $-5.22M |
EPS (Diluted) | $-0.08 | $0.07 | $0.25 | $0.18 | $0.12 |
Total Assets | Not available | $13.13M | $15.99M | $17.41M | $19.67M |
Total Liabilities | Not available | $2.44M | $2.89M | $2.17M | $2.41M |
Cash & Equivalents | Not available | $4.14M | $7.11M | $8.57M | $10.86M |
Free Cash Flow OCF − CapEx | Not available | $-3.09M | $-7.48M | $-5.62M | $-3.07M |
Shares Outstanding | Not available | 46.62M | 46.18M | 45.66M | 45.45M |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.